Pharmacological blockade of the EP3 prostaglandin E2 receptor in the setting of type 2 diabetes enhances β-cell proliferation and identity and relieves oxidative damage.
Bosma KJ, Andrei SR, Katz LS, Smith AA, Dunn JC, Ricciardi VF, Ramirez MA, Baumel-Alterzon S, Pace WA, Carroll DT, Overway EM, Wolf EM, Kimple ME, Sheng Q, Scott DK, Breyer RM, Gannon M.
Bosma KJ, et al. Among authors: pace wa.
Mol Metab. 2021 Dec;54:101347. doi: 10.1016/j.molmet.2021.101347. Epub 2021 Oct 6.
Mol Metab. 2021.
PMID: 34626853
Free PMC article.